in vivo News and Research

RSS

Insect virus holds key to safer stem cell therapy: Singapore scientists

The future of regenerative medicine lies in harnessing the potential of the human body to renew and repair itself. Now, scientists at the Institute of Bioengineering and Nanotechnology (IBN), the world's first bioengineering and nanotechnology research institute, have developed a new genetic engineering technique that promises safer stem cell therapy for cancer patients. Using an insect virus, the team of researchers successfully inserted a therapeutic gene into a safe site in the DNA of human embryonic stem cells without compromising the functionality of the engineered cells.

28 Jul 2011

Substances found in cigarette smoke damage blood vessels' endothelial cells

A research term headed by David Bernhard from the University Department of Surgery at the Medical University of Vienna has found out that substances found in cigarette smoke lead to blood vessels' endothelial cells constantly digesting themselves.

26 Jul 2011

BioWa, arGEN-X sign license agreement for POTELLIGENT Technology

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody platform, announces it has signed a non-exclusive license agreement with BioWa Inc., the exclusive worldwide licensor of POTELLIGENT Technology.

26 Jul 2011

'Core-shell' nanoparticles for effective intracellular delivery of RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, together with collaborators at the Massachusetts Institute of Technology (MIT), announced today the publication of new paper describing discovery of "core-shell" nanoparticles for systemic delivery of RNAi therapeutics.

26 Jul 2011

Researchers characterise protein complex linked to malaria and toxoplasmosis

Maryse Lebrun, Research Director at Inserm, and her fellow researchers at the Laboratoire Dynamique des interactions membranaires normales et pathologiques, have characterised a protein complex that allows the agents that cause malaria and toxoplasmosis to infect host cells.

25 Jul 2011

Maltodextrin-based imaging probes could improve diagnosis and treatment of bacterial infections

A new family of contrast agents that sneak into bacteria disguised as glucose food can detect bacterial infections in animals with high sensitivity and specificity. These agents -- called maltodextrin-based imaging probes -- can also distinguish a bacterial infection from other inflammatory conditions.

21 Jul 2011

Adamis' APC-300 inhibits growth of prostate cancer cells

Adamis Pharmaceuticals Corporation announced today that in addition to activity in pancreatic cancer and its multiple modes of action, APC-300 significantly inhibits the growth of prostate cancer cells.

21 Jul 2011

Gel Company, Biomerix partner to market and distribute 3D Scaffold

Biomerix Corporation and Gel Company today announced a strategic distribution agreement for the Biomerix 3D Scaffold, a novel three-dimensional tissue scaffold. Under the agreement, Gel Company will market and distribute the Biomerix 3D Scaffold to researchers in the life science community across the United States.

20 Jul 2011

Researchers identify potential therapeutic target for ER-negative breast cancer

Using a new in vivo screening system, Whitehead Institute researchers have identified a protein in the serine biosynthesis pathway that is essential in estrogen receptor (ER)-negative breast cancer—a notoriously difficult disease to treat associated with low five-year survival rates.

19 Jul 2011

Scientists find way to make copper-catalyzed click chemistry biocompatible

Biomolecular imaging can reveal a great deal of information about the inner workings of cells and one of the most attractive targets for imaging are glycans - sugars that are ubiquitous to living organisms and abundant on cell surfaces. Imaging a glycan requires that it be tagged or labeled. One of the best techniques for doing this is a technique called click chemistry.

19 Jul 2011

NSVascular signs exclusive license with UCLA for Thin-Film Nitinol technology

NeuroSigma, Inc., a Los Angeles-based medical device company, today announced the formation of a majority owned subsidiary, NSVascular, Inc. and the signing of an exclusive license with the University of California, Los Angeles (UCLA) covering its medical applications of Thin-Film Nitinol (TFN) technology. Nitinol is a superelastic nickel and titanium alloy with unique properties that allow deformation and subsequent full recovery of the original shape upon exposure to body heat.

18 Jul 2011

Neuralstem receives U.S. patent allowance for three new neurogenic compounds

Neuralstem, Inc. announced that it has received notice of allowance for U.S. Patent Applications 12/939,897 and 12/939,914 entitled: "Compositions to Effect Neuronal Growth."

15 Jul 2011

Scientists identify new metabolic pathway for breast cancer

Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, announced today a publication in the journal Nature that identifies dysregulated activity of the serine pathway as a novel metabolic target in certain breast cancers.

15 Jul 2011

New method to study neuronal activity in the deepest layers of the cortex

Visual and tactile objects in our surroundings are translated into a perception by complex interactions of neurons in the cortex. The principles underlying spatial and temporal organization of neuronal activity during decision-making and object perception are not all understood yet.

13 Jul 2011

Celprogen develops neuronal stem cells to treat Alzheimer's

Celprogen has developed neuronal stem cells that can be differentiated into neurons as an alternative for Cell based therapy for neurological diseases including Alzheimer's patients.

13 Jul 2011

Cancer Cell publishes Epizyme and collaborators' breakthrough research on MLL

Epizyme, Inc., a company leading the discovery and development of personalized therapeutics for genetically-defined cancer and rare disease patients, and its collaborators announced the publication in Cancer Cell of breakthrough research in the treatment of MLL-rearranged leukemia (MLL), a genetically-defined subset of acute lymphoblastic leukemia and acute myelogenous leukemia.

12 Jul 2011

InVivo files biopolymer scaffold IDE with FDA to initiate spinal cord injury clinical trial

InVivo Therapeutics today announced that the Company has submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) for a proprietary biopolymer scaffolding device to protect and support spinal tissue and prevent secondary injury, including inflammation and glial scarring, following traumatic spinal cord injury.

8 Jul 2011